X4 Pharmaceuticals (XFOR) Non-Current Debt (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Non-Current Debt for 10 consecutive years, with $76.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Debt rose 1.21% year-over-year to $76.8 million; the trailing twelve-month figure through Jun 2026 stood at $76.8 million (up 1.21% YoY), and the FY2025 full-year result was $76.3 million, up 1.15% from the prior year.
• Non-Current Debt held at $76.8 million in Q2 2026 per XFOR's latest filing, from $76.5 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $76.8 million in Q2 2026 and bottomed at $32.5 million in Q1 2022.
• Historically, Non-Current Debt has averaged $57.9 million across 5 years, with a median of $65.0 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Non-Current Debt declined 3.11% in 2022, then soared 130.86% in 2024.
• Over 5 years, Non-Current Debt stood at $32.5 million in 2022, then soared by 69.23% to $55.0 million in 2023, then surged by 37.14% to $75.4 million in 2024, then gained by 1.15% to $76.3 million in 2025, then climbed by 0.61% to $76.8 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $76.8 million, $76.5 million, and $76.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.